trending Market Intelligence /marketintelligence/en/news-insights/trending/7xo2b38uwte89etx81cthg2 content esgSubNav
In This List

Biocept undertakes 1-for-30 reverse stock split

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


Biocept undertakes 1-for-30 reverse stock split

Biocept Inc. undertook a 1-for-30 reverse split of its common stock, effective July 6.

The San Diego-based molecular oncology diagnostics company expects its stock will begin trading on the Nasdaq Capital Market on a split-adjusted basis July 10.

In January, Biocept received a notice of noncompliance from Nasdaq for failing to maintain the minimum bid price requirement of $1 per share.

The company had a grace period of 180 days to regain compliance with the listing standards of Nasdaq.